Bevacizumab Combined With S-1 and Raltitrexed for Metastatic CRC Refractory to Standard Therapies
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Oncologist
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Bevacizumab Combined With S-1 and Raltitrexed for Patients With Metastatic Colorectal Cancer Refractory to Standard Therapies: A Phase II Study
Oncologist 2021 Apr 08;[EPub Ahead of Print], Y Chen, YW Zhou, K Cheng, ZP Li, DY Luo, M Qiu, Q Li, X Wang, YL Shen, D Cao, Y Yang, F Bi, JY Liu, HF GouFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.